Centre moves to tighten controls on antibiotic manufacturing, bulk drug trade

NEW DELHI: In a move to tighten oversight of the pharmaceutical supply chain and tackle antimicrobial resistance (AMR), the Centre has proposed stricter controls on both the manufacturing and wholesale distribution of antibiotics and other bulk drugs. Under the proposed changes, fresh manufacturing licences for antimicrobials will require prior central approval, while wholesalers dealing in bulk drugs, including active pharmaceutical ingredients (APIs), will need a separate licence to improve monitoring of their movement.In a draft notification, the Union health ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to include antimicrobials in the definition of a ‘new drug’. This would require manufacturers seeking fresh licences to first obtain permission from the Central Licensing Authority (CLA) before approaching state licensing authorities for a manufacturing licence. Existing manufacturing licences will remain valid and will not require fresh central approval.The ministry’s move follows concerns that antimicrobial manufacturing licences are being granted without adequate quality checks, including bioavailability, bioequivalence and stability studies. The proposed central scrutiny is aimed at ensuring the quality and efficacy of medicines, as substandard or ineffective antimicrobials can contribute to drug resistance and make infections harder to treat.Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites develop resistance to medicines used to treat infections, making treatment more difficult and increasing the risk of prolonged illness, complications and deaths.Separately, the ministry has proposed a separate application form and licence for bulk drug wholesalers under the Drugs Rules, 1945. Currently, a common wholesale licence covers both bulk drugs and finished medicines. The new framework will require sales to be supervised by a competent person and licences to specify the categories of bulk drugs handled, including those covered under the NDPS Act. The move aims to improve tracking, curb diversion of controlled substances and strengthen oversight of bulk antibiotics amid AMR concerns.

Share your thoughts in the comments